Growth Metrics

Vera Therapeutics (VERA) Long-Term Deferred Tax (2023)

Vera Therapeutics posted quarterly Long-Term Deferred Tax of $72.1 million for Q4 2023.

Vera Therapeutics (VERA) has 1 years of Long-Term Deferred Tax data on file, last reported at $72.1 million in Q4 2023.

  • For the quarter ending Q4 2023, Long-Term Deferred Tax changed N/A year-over-year to $72.1 million; the trailing twelve-month figure through Dec 2023 stood at $72.1 million (changed N/A YoY), and the FY2023 full-year result was $72.1 million, changed N/A from the prior year.
  • Long-Term Deferred Tax for Q4 2023 stood at $72.1 million.
  • Across five years, Long-Term Deferred Tax topped out at $72.1 million in Q4 2023 and bottomed at $72.1 million in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Vera Therapeutics 2.43 Bn 1.83 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 72.09 Mn